Kreztel-MT 25 Tablet ER is a combination antihypertensive medication containing Telmisartan 40 mg and Metoprolol Succinate 25 mg, formulated as an extended-release tablet for once-daily administration. Telmisartan, an angiotensin II receptor blocker (ARB), selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Metoprolol Succinate, a cardioselective beta-1 adrenergic receptor blocker, reduces heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and improved cardiac workload. The combination of these two agents offers complementary mechanisms for effective management of hypertension, particularly in patients requiring dual therapy for optimal control. Kreztel-MT 25 is indicated for the treatment of essential hypertension to lower the risk of cardiovascular events such as stroke and myocardial infarction. The extended-release formulation ensures sustained plasma concentrations, enhancing patient compliance and minimizing fluctuations in blood pressure. Caution is advised in patients with bradycardia, heart block, or severe hepatic impairment. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. Kreztel-MT 25 should be used under medical supervision, adhering to prescribed dosage and contraindications.